Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation

Coron Artery Dis. 2010 Aug;21(5):273-7. doi: 10.1097/MCA.0b013e32833b20f1.

Abstract

Background: This study sought to examine whether circulatory levels of endothelial dysfunction biomarkers [vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1), sE-selectin, von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1)] are associated with occurrence of late or very late stent thrombosis (ST) after percutaneous coronary intervention with sirolimus-eluting stent implantation, and to assess the possible influence of genetic variants of these proteins on ST.

Methods: Serum levels of sVCAM-1, sICAM-1, sE-selectin, vWF, t-PA and PAI-1 were measured, and polymorphisms of vWF (-1234C/T, -1185A/G and -1051G/A), t-PA (insertion/deletion) and PAI-1 genes (4G/5G) were determined in 41 patients who experienced at least one episode of late or very late ST. Eighty-two patients without ST randomly selected from the same study period served as controls.

Results: Serum levels of vWF, sVCAM-1 and sICAM-1 were significantly increased in patients with ST than in controls (all P<0.01). No significant difference was observed in the genotype and allele distribution of the vWF, t-PA and PAI-1 gene polymorphisms. Multivariable logistic regression analysis showed that vWF, sVCAM-1, discontinuation of clopidogrel therapy and left ventricular ejection fraction of less than 50% were independent determinants of late ST.

Conclusion: Increased serum vWF and sVCAM-1 levels are associated with late ST, suggesting that endothelial dysfunction contributes to the development of late or very late ST.

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Biomarkers / blood
  • Cardiovascular Agents / administration & dosage*
  • Case-Control Studies
  • Chi-Square Distribution
  • China
  • Coronary Angiography*
  • Drug-Eluting Stents*
  • E-Selectin / blood
  • Female
  • Gene Frequency
  • Humans
  • Intercellular Adhesion Molecule-1 / blood
  • Logistic Models
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Plasminogen Activator Inhibitor 1 / genetics
  • Platelet Aggregation Inhibitors / therapeutic use
  • Polymorphism, Genetic
  • Risk Assessment
  • Risk Factors
  • Sirolimus / administration & dosage*
  • Stroke Volume
  • Thrombosis / blood
  • Thrombosis / diagnostic imaging
  • Thrombosis / etiology*
  • Thrombosis / physiopathology
  • Time Factors
  • Tissue Plasminogen Activator / blood
  • Tissue Plasminogen Activator / genetics
  • Treatment Outcome
  • Vascular Cell Adhesion Molecule-1 / blood*
  • Ventricular Function, Left
  • von Willebrand Factor / genetics
  • von Willebrand Factor / metabolism*

Substances

  • Biomarkers
  • Cardiovascular Agents
  • E-Selectin
  • Plasminogen Activator Inhibitor 1
  • Platelet Aggregation Inhibitors
  • SELE protein, human
  • SERPINE1 protein, human
  • Vascular Cell Adhesion Molecule-1
  • von Willebrand Factor
  • Intercellular Adhesion Molecule-1
  • Tissue Plasminogen Activator
  • Sirolimus